首页> 外文会议>2011 International Conference on Human Health and Biomedical Engineering >Betahistine is effective in combatting spasms in NMDA-inducing infantile spasms rat model
【24h】

Betahistine is effective in combatting spasms in NMDA-inducing infantile spasms rat model

机译:Betahistine在对抗NMDA诱导的婴儿痉挛大鼠模型中有效对抗痉挛

获取原文

摘要

Infantile spasms (IS) is an age-related epileptic disorder characterized by specific spasms, hypsarrhythmia and mental retardation. Most of IS patients can not get spasm free under the available treatment and prognosis is poor. It is crucial to develop new effective drugs the treatment of IS. Histamine H3 receptor antagonist seems to be effective in some epilepsy models. Betahistine is one of H3 antagonists. For this purpose, we tested the effecacy of betahistine in a NMDA-induced IS model. The results showed that betahistine prolonged the latencies to tail-flicking and emprothonus and decreased the incidence of stereotypic behaviors in IS rats. Betahistine has increased histamine content and H3 receptor expression in the brain in a dosage-dependent manner. Then, betahistine exerts it anti-spasms effect through increaing histamine content and H3 expression. It is promising for H3 antagonists use in IS in clinic to control spasms and improve the poor prognosis.
机译:婴儿痉挛症(IS)是一种与年龄有关的癫痫病,其特征在于特定的痉挛,hypera律失常和智力低下。在可用的治疗方法下,大多数IS患者无法获得无痉挛,并且预后较差。开发治疗IS的新有效药物至关重要。组胺H3受体拮抗剂似乎在某些癫痫模型中有效。 Betahistine是H3拮抗剂之一。为此,我们在NMDA诱导的IS模型中测试了倍他司汀的功效。结果表明,倍他司丁延长了甩尾和垂尾肌的潜伏期,降低了IS大鼠刻板行为的发生率。 Betahistine以剂量依赖性方式增加了脑中组胺含量和H3受体的表达。然后,倍他司汀通过增加组胺含量和H3表达来发挥抗痉挛作用。 H3拮抗剂有望在临床中用于IS来控制痉挛并改善不良预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号